Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?

Maiorino MI, Petrizzo M, Capuano A, Giugliano D, Esposito K.

Expert Opin Biol Ther. 2014 Jun;14(6):799-808. doi: 10.1517/14712598.2014.895812. Epub 2014 Mar 27. Review.

PMID:
24673155
2.

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

Owens DR, Matfin G, Monnier L.

Diabetes Metab Res Rev. 2014 Feb;30(2):104-19. doi: 10.1002/dmrr.2469. Review.

PMID:
24026961
3.

Will the next generation of basal insulins offer clinical advantages?

Garber AJ.

Diabetes Obes Metab. 2014 Jun;16(6):483-91. doi: 10.1111/dom.12219. Epub 2013 Oct 31. Review.

PMID:
24118819
4.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.

Koivisto V, Cleall S, Pontiroli AE, Giugliano D.

Diabetes Obes Metab. 2011 Dec;13(12):1149-57. doi: 10.1111/j.1463-1326.2011.01484.x.

PMID:
21819517
5.

Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.

Khunti K, Cos X, Rutten G.

Prim Care Diabetes. 2014 Jul;8(2):119-25. doi: 10.1016/j.pcd.2013.09.003. Epub 2013 Oct 25. Review.

6.

Humalog (lispro) for type 2 diabetes.

Esposito K, Capuano A, Giugliano D.

Expert Opin Biol Ther. 2012 Nov;12(11):1541-50. Review.

PMID:
23043233
7.

[New insulin types in type 1 diabetes mellitus].

Mesa J.

Med Clin (Barc). 2015 Jul 20;145(2):70-5. doi: 10.1016/j.medcli.2014.04.024. Epub 2014 Sep 4. Review. Spanish.

PMID:
25200067
8.

Newer insulin analogs: advances in basal insulin replacement.

Zinman B.

Diabetes Obes Metab. 2013 Mar;15 Suppl 1:6-10. doi: 10.1111/dom.12068. Review.

PMID:
23448197
9.

New Insulins and New Aspects in Insulin Delivery.

Woo VC.

Can J Diabetes. 2015 Aug;39(4):335-43. doi: 10.1016/j.jcjd.2015.04.006. Review.

PMID:
26233724
10.

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.

Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J.

Diabet Med. 2012 Sep;29(9):e263-72. doi: 10.1111/j.1464-5491.2012.03722.x. Erratum in: Diabet Med. 2012 Nov;29(11):1473. Felicio, J [corrected to Felicio, J S].

PMID:
22672081
11.

PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.

Caparrotta TM, Evans M.

Diabetes Obes Metab. 2014 May;16(5):388-95. doi: 10.1111/dom.12196. Epub 2013 Sep 12. Review.

PMID:
23941279
12.

Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.

Esposito K, Giugliano D.

Expert Opin Biol Ther. 2012 Feb;12(2):209-21. doi: 10.1517/14712598.2012.648181. Epub 2012 Jan 4. Review.

PMID:
22214489
14.

Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.

Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals JM.

Diabetes Obes Metab. 2014 Apr;16(4):351-6.

PMID:
24719911
15.

Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.

Sakharova OV, Lleva RR, Dziura JD, Spollett GR, Howell SK, Beisswenger PJ, Inzucchi SE.

J Diabetes Complications. 2012 Jul-Aug;26(4):333-8. doi: 10.1016/j.jdiacomp.2012.03.027. Epub 2012 Apr 26.

PMID:
22541894
16.

Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.

Muñoz Torres M.

Endocrinol Nutr. 2014 Mar;61(3):153-9. doi: 10.1016/j.endonu.2013.03.012. Epub 2013 Jul 25. Review.

PMID:
23890782
17.

Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.

Kumar A.

Expert Opin Biol Ther. 2014 Jun;14(6):869-78. doi: 10.1517/14712598.2014.904851. Epub 2014 Apr 5. Review.

PMID:
24702171
18.

Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.

Giugliano D, Tracz M, Shah S, Calle-Pascual A, Mistodie C, Duarte R, Sari R, Woo V, Jiletcovici AO, Deinhard J, Wille SA, Kiljanski J.

Diabetes Care. 2014 Feb;37(2):372-80. doi: 10.2337/dc12-2704. Epub 2013 Oct 29.

PMID:
24170763
19.

Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data.

Ceriello A, Cremasco F, Romoli E, Rossi A, Gentilella R.

Expert Opin Pharmacother. 2012 Feb;13(2):255-81. doi: 10.1517/14656566.2012.650862. Epub 2012 Jan 13. Review.

PMID:
22242803
20.

Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.

Esposito K, Chiodini P, Capuano A, Petrizzo M, Improta MR, Giugliano D.

Diabetes Care. 2012 Dec;35(12):2698-705. doi: 10.2337/dc12-0698.

Supplemental Content

Support Center